Fernando Kreutz
Founder & Chief Executive Officer CellVax Therapeutics
Dr. Fernando Thomé Kreutz is the Founder and CEO of CellVax Therapeutics Inc., a biotechnology company developing personalized cellular immunotherapies for cancer. Trained as a physician and holding a PhD in Biotechnology from the University of Alberta, he has over two decades of experience in translational research and innovation. Dr. Kreutz has authored multiple patents and publications in immunodiagnostics, nanotechnology, and cancer immunotherapy. He currently leads the development of the Tumor Presenting Cell (TPC) platform, with clinical programs advancing in the United States.
Seminars
Wednesday 22nd July 2026
Beyond Neoantigen Prediction: Using the Patient’s Own Tumour to Drive Personalised Cancer Vaccines
10:30 am
- Presentation of CellVax’s Tumour Presenting Cell (TPC) platform, a personalised cancer vaccine approach that leverages the patient’s own tumour cells to present the full repertoire of tumour antigens without the need for neoantigen prediction algorithms
- Clinical and translational insights from the ongoing Phase 2 trial of FK-PC101 in high risk prostate cancer patients following prostatectomy, including immune activation signals and long-term immunological responses
- How a tumour-derived antigen presentation may enable a simpler, faster, and potentially more scalable pathway for personalised cancer vaccines compared to sequencing-driven neoantigen approaches
